Alpa Laboratories' Q2 FY 2025-26 Quarterly Results
- 16 Nov 2025
Result Summary
- Alpa Laboratories Ltd reported a 5.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 7.9%.
- Its expenses for the quarter were up by 51.4% QoQ and 31.5% YoY.
- The net profit decreased 99.1% QoQ and decreased 98.6% YoY.
- The earnings per share (EPS) of Alpa Laboratories Ltd stood at 0.05 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 29.32 | 31.06 | 31.85 | -5.6% | -7.9% |
Total Expenses | 29.20 | 19.29 | 22.20 | 51.4% | 31.5% |
Profit Before Tax | 0.11 | 11.77 | 9.65 | -99.1% | -98.9% |
Tax | 0.00 | 0.00 | 1.96 | - | -100.0% |
Profit After Tax | 0.11 | 11.77 | 7.69 | -99.1% | -98.6% |
Earnings Per Share | 0.05 | 5.59 | 3.66 | -99.1% | -98.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alpa Laboratories Ltd is a company engaged in the pharmaceutical industry, focusing on the production and marketing of generic drugs and formulations. The company typically operates in the healthcare sector, manufacturing a range of products including tablets, injectables, and ointments. It caters to both domestic and international markets, contributing to the healthcare needs across various geographies. As of the latest updates, there are no specific major developments reported for Alpa Laboratories Ltd that could influence its current operations or financial performance.
Revenue
For the quarter ending Q2FY26, Alpa Laboratories Ltd reported a total income of ₹29.32 crores. This marks a decrease of 5.6% from the previous quarter (Q1FY26), where the total income was ₹31.06 crores. Additionally, when comparing year-over-year (YoY) performance, there is a 7.9% decline from Q2FY25, when the total income was ₹31.85 crores. This reflects a trend of decreasing revenue over the periods considered, indicating a contraction in income generation activities within the timeframe of the data provided.
Profitability
The financial data for Q2FY26 indicates a significant decline in profitability for Alpa Laboratories Ltd. The Profit Before Tax (PBT) was reported at ₹0.11 crores, a sharp decrease of 99.1% quarter-over-quarter (QoQ) from ₹11.77 crores in Q1FY26, and a similar 98.9% decline year-over-year from ₹9.65 crores in Q2FY25. The Profit After Tax (PAT) for Q2FY26 also mirrors this trend, standing at ₹0.11 crores, down from ₹11.77 crores in Q1FY26 and ₹7.69 crores in Q2FY25, representing a 99.1% QoQ and 98.6% YoY decrease. These figures highlight a significant reduction in the company's profitability over the specified periods.
Operating Metrics
The operating metrics for Alpa Laboratories Ltd, as reflected in the financial data, show a notable increase in total expenses. In Q2FY26, total expenses amounted to ₹29.20 crores, marking a 51.4% increase QoQ from ₹19.29 crores in Q1FY26 and a 31.5% increase YoY from ₹22.20 crores in Q2FY25. This rise in expenses significantly impacts the overall financial health and operating efficiency of the company. Additionally, the Earnings Per Share (EPS) for Q2FY26 was ₹0.05, which represents a 99.1% QoQ and 98.6% YoY decrease from ₹5.59 in Q1FY26 and ₹3.66 in Q2FY25, respectively. These metrics illustrate a challenging operational environment for the company during the periods assessed.